Sanofi Ends EU Probe Over Flu Vaccine Claims

Sanofi Bows to EU Antitrust Probe Over CSL Flu Shot Smears

Sanofi offered on July 8, 2026 to stop disparaging CSL's Fluad vaccine in Europe. The commitments dodge a fine of up to 10% of global sales — and set an antitrust template Brussels is now running twice.

Sanofi has offered the European Commission a package of behavioural commitments to halt what regulators call a disparagement campaign against CSL Seqirus's Fluad flu vaccine in France and Germany, moving to end an Article 102 abuse-of-dominance probe that could otherwise have exposed the French drugmaker to a fine of up to 10% of its global annual turnover — north of €4 billion on 2025 sales. The deal, published for market test on July 8 with a comment deadline of August 21, is the second time in two years Brussels has extracted the same remedy from a dominant pharma firm accused of badmouthing a rival: the complainant this time is the corporate sibling of the last defendant. That symmetry, more than the vaccines involved, is what makes this case a template.

The Commission opened the formal investigation on June 26, 2026 — though the Endpoints News account of the filing notes the probe was first opened in September 2025, with the formal Article 102 framing adopted in June 2026, alleging that Sanofi's promotion of its high-dose quadrivalent Efluelda in France and Germany crossed from competitive marketing into "objectively misleading" communications about the only comparably enhanced flu vaccine recommended for vulnerable elderly patients, CSL Seqirus's MF59-adjuvanted Fluad. Under Directorate-General for Competition framing, such conduct — if left unchecked — "may have restricted competition" in the two largest EU markets for enhanced flu shots. Under Article 102 TFEU, the maximum sanction is 10% of worldwide turnover.

Sanofi's response was to skip the fight. Within twelve days it offered commitments under Article 9 of Regulation 1/2003 — the same procedural route Vifor used in 2024 — that would run until March 2030. The core undertakings, first reported by Reuters (Foo Yun Chee and Inti Landauro), are three: publish a corrective notice for two years on its French and German websites confirming that national vaccination technical advisory groups recommend Efluelda and Fluad equally for the elderly; refrain from portraying Fluad negatively or suggesting Efluelda is safer or more effective; and stop mischaracterising scientific studies involving the rival product. Sanofi told the Commission the offer implies "no finding of infringement" and that it "remains confident it has acted in full compliance with all applicable laws," according to the same Endpoints News account of the filing, which quotes Sanofi's written statement to the Commission directly.

The playbook is now unmistakable

The Vifor case is the tell. In July 2024, the Commission accepted commitments from CSL Vifor — a subsidiary of the same Australian-Swiss group that owns CSL Seqirus — to end alleged disparagement of Pharmacosmos's Monofer intravenous iron treatment. The remedies were near-identical in architecture: a multi-channel corrective communication to healthcare professionals, a prohibition on safety claims not grounded in Monofer's own label or head-to-head trials, monitoring trustee, no admission of liability. The prohibition period runs ten years. The UK's Competition and Markets Authority mirrored the package in May 2025, tacking on a £23 million ex-gratia payment to the NHS specific to Britain.

Two features of that template matter for reading the Sanofi filing. First, the Vifor case reached a formal commitments decision published in the EU Official Journal on November 6, 2024, giving Brussels a settled legal precedent it can copy-paste. Second, no fine was imposed and no infringement was ever concluded — a structural feature of Article 9, whose recitals in Council Regulation 1/2003 explicitly bar "commitment decisions" from doing the work of prohibition decisions. That is the deal every dominant pharma firm now knows is on the table: accept a decade of behavioural constraint, keep the ten-figure headline fine off the books, walk away without an admission that could be used in follow-on damages litigation.

Sanofi is buying the same insurance. Its parallel to Vifor's package is close enough that the market-test document reads like a copy with variables swapped: rival product name, geographies, corrective-notice duration. The French drugmaker reported first-quarter 2026 revenue of €10.5 billion, on track for another year above €40 billion, meaning any 10% ceiling would run into the low-single-digit billions of euros. Two years of a website notice is cheaper than four years of appellate litigation and a nine-figure fine that would show up in the 2026 annual report.

What Efluelda is actually worth defending

Efluelda is not a peripheral product. It is Sanofi's answer to the demographic reality that adults 65 and over account for the overwhelming majority of influenza deaths in Europe. High-dose quadrivalent flu vaccine contains four times the antigen of standard vaccines and was rolled out across major European markets from the 2021–22 season. A large French retrospective cohort published in Clinical Microbiology and Infection — 405,385 Efluelda recipients matched 1:4 against standard-dose vaccinees — found a 23.3% lower rate of influenza hospitalisations, which Sanofi has leaned on hard in its French and German commercial messaging.

The Commission's problem is not that message. It is what came next. Germany's Standing Committee on Vaccination (STIKO) formally adjusted its position in October 2024, recommending the MF59-adjuvanted vaccine as equivalent to the high-dose one for adults over 60 based on evidence of comparable effectiveness and a similar safety profile. That put Fluad and Efluelda on the same institutional footing in the EU's largest vaccine market. Once regulators had graded the two products as equivalent, any Sanofi communication implying superiority — beyond what the labels or head-to-head trials support — became legally exposed.

CSL Seqirus itself is not a small player being crushed. It is one of only three global bulk influenza vaccine producers with market presence in more than ten countries, per the WHO's 2024 global market study of seasonal influenza vaccines. But in the specific segment of enhanced vaccines for the elderly — the fastest-growing, highest-margin corner of the flu market — CSL's Fluad and Sanofi's Efluelda are the only two products in most European elderly-indication schedules, as the UKHSA's 2026–27 season list makes plain. It is a duopoly. Marginal share moves inside it are worth eight-figure sums per season, per country.

The non-obvious angle: CSL sits on both sides of the ledger

The overlooked feature of this case is who benefits. CSL, the Melbourne-listed parent, has just executed the most efficient bit of regulatory arbitrage in European pharma in years. Its Vifor arm accepted a 10-year behavioural cage on IV iron in July 2024. Its Seqirus arm is now the beneficiary of a near-identical cage being fitted on Sanofi in the flu-vaccine market — the very market where Seqirus most wants Fluad reimbursed on equal terms with Efluelda in Berlin, Paris and Madrid. There is no evidence the two proceedings are linked — and there does not need to be. The Commission has developed a workable template, and any dominant incumbent whose sales rep talks down a competitor is now a candidate for it.

Losers are easier to name. Sanofi loses the option of asymmetric marketing muscle in the two markets where Efluelda's early lead was widest. National sick funds in France and Germany lose the tacit tiebreaker that Sanofi's messaging created — a hidden argument for paying the price premium for high-dose over adjuvanted vaccines. A CSL-sponsored cost-effectiveness analysis in Germany concluded, based on similar clinical effectiveness, that Fluad is cost-saving versus Efluelda at prevailing prices — a claim that had until now bumped into Sanofi's counter-marketing every autumn tender cycle. That friction is what the corrective notice is designed to remove.

What to watch

The August 21 market-test deadline is the first decision point. Third parties — including CSL Seqirus itself, any national sick fund that reimbursed Efluelda over Fluad, and possibly generic and biosimilar rivals eyeing the elderly-flu segment — can push for tighter commitments. In Vifor, the market test forced a widening of the corrective communication and a longer prohibition. Expect the same lever pulled here: pressure to extend the two-year website notice, add print communications to prescribers, and lengthen the 2030 prohibition sunset closer to Vifor's decade.

Three concrete catalysts over the next 12 months:

• August 21, 2026 — close of the Article 9 market test; the Commission decides whether to accept the commitments as filed, seek modifications, or open a full prohibition track.
• Autumn 2026 — first flu season under a would-be Sanofi corrective notice. National tender outcomes in Germany's statutory-health-insurance framework will indicate whether CSL Seqirus is clawing back share.
• Q1 2027 Sanofi results — Efluelda's growth curve, disclosed in vaccines segment reporting, will be the cleanest quantitative read on how much the corrective notice actually costs.

The revision condition for the forecast below is a decision by DG-COMP to reject Sanofi's package and pursue an infringement decision with fines. If Brussels does that — after twice choosing Article 9 for pharma disparagement — it will signal the template has been abandoned. Nothing in the July 8 filings suggests that is coming.

Diplomat View

Brussels has quietly built a two-case template for policing dominant-firm speech in pharma without ever running the trial. The Sanofi settlement, if accepted in August, cements that template: a preliminary assessment under Article 102 TFEU, a fast Article 9 commitment package under Regulation 1/2003, a multi-year corrective communication, a behavioural cage lasting through 2030, no fine, no admission. It is a low-cost, high-yield enforcement product for DG-COMP, and it will now be used again. The forecast: within eighteen months a third dominant European drugmaker — most likely in oncology or specialty biologics, where head-to-head messaging is most aggressive — will be probed under the same architecture. The condition that would falsify the forecast is Brussels rejecting Sanofi's offer and pursuing a formal infringement decision, which would signal the Commission has decided the disparagement doctrine now needs a precedent with teeth rather than a settlement without them. The third case, when it comes, will be the tell — not the settlement, but whether Brussels demands teeth.

Key Takeaways

• Sanofi offered EU antitrust commitments on July 8, 2026 to end alleged disparagement of CSL Seqirus's Fluad flu vaccine in France and Germany, twelve days after the Commission opened a formal probe.
• The package mirrors the 2024 CSL Vifor settlement almost line-for-line — corrective communications, prohibited safety claims not grounded in the label or head-to-head trials, monitoring trustee, no admission of liability.
• Under Article 9 of EU Regulation 1/2003, Sanofi avoids the risk of a fine of up to 10% of global turnover — over €4 billion at 2025 revenue.
• CSL is the unlikely double-beneficiary of Brussels' new template: its Vifor arm negotiated it in 2024, its Seqirus arm collects on it in 2026.
• Market-test deadline is August 21, 2026. The Commission's decision to accept, modify, or reject the commitments will define the template for the next wave of pharma disparagement cases.